Abstract
Recently,we have read with great interest Dr. Espriella and colleagues' article [1] that published in International Journal of Cardiology. In Dr. Espriella et al.'s study, they elucidated the effects of empagliflozin on CA125 trajectory in patients with chronic congestive heart failure. It indicated that CA125 played a critical role in patients with chronic congestive heart failure and that may be beneficial in discovering a promising option for patients with chronic congestive heart failure.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
